<DOC>
	<DOCNO>NCT01746732</DOCNO>
	<brief_summary>The purpose study evaluate effect evacetrapib oral contraceptive ( Ortho-CyclenÂ® ) give healthy female participant . The amount female hormone find blood measure compare take alone take evaceptrapib . Each woman participate two study period . Information side effect may occur also collect .</brief_summary>
	<brief_title>A Study Evacetrapib Healthy Female Participants</brief_title>
	<detailed_description />
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Are premenopausal female , healthy determine medical history physical examination Have body mass index 18 30 kilogram per square meter ( kg/m^2 ) Have know allergy evacetrapib OrthoCyclen ( ethinyl estradiol norgestimate ) , related compound component formulation Have clinically significant abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Regularly use know drug abuse and/or show positive finding urinary drug screening Have take injectable contraceptive within 12 month prior first dose leadin period topical control delivery contraceptive ( patch ) 3 month prior first dose leadin period Use tobacco nicotinecontaining product within 6 month prior leadin phase study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>